Concepedia

Daniel A. Gipe

DA

15

Publications

3.6K

Citations

14

H-Index

2014

Active since

Affiliations

Regeneron (United States)(Current)

Sanofi (France)

University of Amsterdam

Amsterdam UMC Location University of Amsterdam

Montreal Clinical Research Institute

Daniel A. Gipe is an author at Regeneron (United States) specializing in medicine, cardiovascular disease, and hematology.

ORCID

Top concepts

Publications per year

2014–2021

15

Publications

15

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Frederick E. Dewey, Viktoria Gusarova, Richard L. Dunbar et al. · New England Journal of Medicine · 2017 · 836 citations · Full text

Evinacumab for Homozygous Familial Hypercholesterolemia

Frederick J. Raal, Robert S. Rosenson, Laurens F. Reeskamp et al. · New England Journal of Medicine · 2020 · 707 citations · Full text

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

John J.P. Kastelein, Henry N. Ginsberg, Gisle Langslet et al. · European Heart Journal · 2015 · 530 citations · Full text

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Patrick M. Moriarty, Paul D. Thompson, Christopher P. Cannon et al. · Journal of clinical lipidology · 2015 · 460 citations · Full text

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

Zahid Ahmad, Poulabi Banerjee, Sara Hamon et al. · Circulation · 2019 · 235 citations · Full text

Rows per page

1–5 of 15